Global GPS IC Market 2011-2015

TechNavio's analysts forecast the Global GPS IC market to grow at a CAGR of 7.5 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing use of GPS ICs in smartphones. The Global GPS IC market has also been witnessing the development of multifunctional GPS ICs. However, the lack of accuracy in GPS information could pose a challenge to the growth of this market.

TechNavio's report, the Global GPS IC Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global GPS IC market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this market space include Broadcom Corp., CSR Plc., Qualcomm Inc., and Texas Instruments Inc.

Other vendors mentioned in the report: Analog Devices Inc., Maxim Integrated Products Inc., and RF Micro Devices.

Key questions answered in this report:

• What will the market size be in 2015 and at what rate will it grow?
• What key trends is this market subject to?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the opportunities and threats faced by each of these key vendors?
• What are the strengths and weaknesses of each of these key vendors? 

Get a copy of this report @ http://www.reportsnreports.com/reports/195669-global-gps-ic-market-2011-2015.html

Non-Life Insurance in Malaysia, Key Trends and Opportunities to 2016

The report provides in depth market analysis, information and insights into the Malaysian non-life insurance market, including:

• The Malaysian non-life insurance market’s growth prospects by non-life insurance categories
• The various distribution channels in the Malaysian non-life insurance market
• The competitive landscape in the non-life insurance market in Malaysia
• A description of the non-life reinsurance market in Malaysia

Executive summary

The expansion of the Malaysian non-life insurance segment was strongly influenced by the country’s GDP growth and the increasing penetration rate of the Malaysian insurance industry. Moreover, the growth of the industry is also expected to be driven by increased risk awareness and propensity for risk avoidance among the Malaysian population. The growth of the country’s property and automobile industries, rising employment levels and anticipated industrial growth over the forecast period are also expected to drive the growth of the non-life insurance segment. In 2011, the motor insurance category accounted for the largest proportion of the Malaysian non-life segment.

Get a copy of this report @ http://www.reportsnreports.com/reports/155944-non-life-insurance-in-malaysia-key-trends-and-opportunities-to-2016.html

Report Details:
Published: October 2012
No. of Pages: 257
Price:Single User License:US$1950 Corporate User License:US$3900



Scope
This report provides a comprehensive analysis of the non-life insurance market in Malaysia:

• It provides historical values for Malaysia’s non-life insurance market for the report’s 2007–2011 review period and forecast figures for the 2012–2016 forecast period
• It offers a detailed analysis of the key sub-segments in Malaysia’s non-life insurance market, along with market forecasts until 2016
• It covers an exhaustive list of parameters, including written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, frauds and crimes, total assets, total investment income and retentions
• It analyses the various distribution channels for non-life insurance products in Malaysia
• Using Porter’s industry-standard “Five Forces” analysis, it details the competitive landscape in Malaysia for the non-life insurance business
• It provides a detailed analysis of the reinsurance market in Malaysia and its growth prospects
• It profiles the top non-life insurance companies in Malaysia and outlines the key regulations affecting them

Key highlights

• The expansion of the Malaysian non-life insurance segment was strongly influenced by the country’s GDP growth and the increasing penetration rate of the Malaysian insurance industry.
• In 2011, the motor insurance category accounted for the largest proportion of the Malaysian non-life segment.
• The growth of the industry is also expected to be driven by increased risk awareness and the propensity for risk avoidance among the Malaysian population.
• Although the agencies distribution channel dominates Malaysian non-life insurance, bancassurance is expected to record the strongest growth over the forecast period.

Reasons to buy

• Make strategic business decisions using historic and forecast market data related to the Malaysian non-life insurance market and each sector within it
• Understand the demand-side dynamics, key market trends and growth opportunities within the Malaysian non-life insurance market
• Assess the competitive dynamics in the non-life insurance market, along with the reinsurance segment
• Identify the growth opportunities and market dynamics within key product categories
• Gain insights into key regulations governing the Malaysian insurance market and its impact on companies and the market's future

Progress in Target Validation

Target validation is one of the first and most important steps in drug discovery; poor target validation is a major factor in clinical stage attrition. Target validation involves the thorough assessment of a molecular target, evaluating its physiology, pathology, and pharmacology and determining its role in altering the disease phenotype. This report assess technological advances in the field.

Features and benefits

• Discover how and patient-derived human primary cells and induced pluripotent stems cells lines are being used to validate new drug targets.
• Understand how RNAi technology can be applied to both in vitro and in vivo settings to confirm the involvement of targets in disease pathways.
• Identify the omic technologies that are being used reveal new options for modulating disease pathways and new interactions of known drugs.
• Understand the power of high-content screening in probing functional changes occurring at the cellular level.
• Assess the role of bioinformatics in managing the vast quantities of data that are being created through target validation projects. 

Get a copy of this report @ http://www.reportsnreports.com/reports/195678-progress-in-target-validation.html

Report Details:
Published: September 2012
No. of Pages: 44
Price:Single User License:US$2875 Corporate User License:US$10781


Highlights

In recent years there has been a paradigm shift, with greater emphasis placed on the validation of a target in human cell and animal disease models prior to screening for lead compounds. This facilitates in-depth knowledge of the underlying biology of a disease and allows evaluation of upstream and downstream pathways of new targets.

RNAi-based technologies offer high throughput, a high-predictive value, relatively low cost, short experimental times, and the ability to knock down several genes in vitro and in vivo.

Improvements in molecular imaging and bioinformatics have enabled high-content screening to become more widely applied to measure phenotypic endpoints, allowing structural and biochemical changes within cells, tissues, organs, or whole organisms to be visualized in real time, leading to improvements in target validity.

Your key questions answered

• What novel technologies have been developed to improve target validation in vivo?
• What role do systems biology and network pharmacology have in target valdiation?
• Which companies are leading the field in the use of in vivo models in target validation?
• What opportunities do stem cells offer for validating targets?

Product Profiles: Top 20 Oncology Therapy Brands 2011-21

The high level of commercial success experienced by the key companies in the oncology market makes it extremely attractive to drug developers. The treatment of cancer has shifted away from mass market blockbuster cytotoxic drugs toward a more personalized therapy approach. However, government austerity packages could see slower commercial growth and larger generic erosion of key brands.

Features and benefits

• Assess detailed drug information for the leading oncology brands, including detailed clinical trial information for each approved indication
• Understand the key factors that led to the success of the top 20 oncology therapy brands and the obstacles that they have encountered
• Gain insight into the clinical and commercial attractiveness for each of the branded drugs and how this will affect their future sales

Get a copy of this report @ http://www.reportsnreports.com/reports/195675-product-profiles-top-20-oncology-therapy-brands-2011-21.html

Report Details:
Published: September 2012
No. of Pages: 157
Price:Single User License:US$11400 Corporate User License:US$28500



Highlights

Targeted therapies comprise 60% of the top 20 brands in 2011 with Roche’s monoclonal antibody franchise maintaining the top three positions. A potential to demonstrate improved clinical efficacy with reduced off-target toxicity, combined with an ability to demand higher prices, makes this drug class clinically and commercially attractive.

An aging cytotoxic market means that cytotoxic brands are becoming less commercially attractive. In the past few years many of the blockbuster cytotoxics have come off-patent and now face generic erosion. As developers turn their attention toward new targeted therapies the number of new cytotoxics entering the market has decreased.

Antihormonal therapies have high clinical attractiveness, but despite strong sales they are limited to two indications. Effective lifecycle management has ensured that sales remain high despite patent expiries in almost every major market.

Your key questions answered

• Product profiles and development overviews detailing companies involved and the key clinical data leading to each approval
• Overview of brand positioning in marketed indications relative to competitors and in terms of ability to meet unmet needs
• SWOT analysis of each brand in the seven major market top 20
• In depth assessment of each brand’s clinical and commercial attractiveness, including Datamonitor’s drug assessment charts

Fruit Market | Next-Generation Superfruits

This report examines the emerging market of superfruits within the global food and drinks market, analyzing data from four metrics: product launches, patent applications, health claim applications, and clinical trial data. This will enable manufacturers to assess the emerging trends and growth opportunities within the superfruit food and drinks landscape.

Features and benefits

• Use patent application data to see which superfruits are provoking the most interest in terms of research and what is being deemed patentable.
• Use product launch data to identify the target areas for existing superfruit-based products. Understand the product breakdown by category.
• Assess EFSA's opinions and understand what types of claims are being made about which superfruits.
• Identify three up-and-coming superfruits as “ones to watch” in the future.

Get a copy of this report @ http://www.reportsnreports.com/reports/195677-next-generation-superfruits.html

Report Details:
Published: September 2012
No. of Pages: 90
Price:Single User License:US$2875 Corporate User License:US$10781 



Highlights

Blueberry and pomegranate are the most popular superfruits in new food and drink launches. But novel fruits are gaining ground, with chokeberry, jujube, and seabuckthorn being notable examples. Over 400 new food and drink products containing seabuckthorn were launched in 2009–12, the majority of which hit shelves in Russia, Germany, and France.

A high proportion of health claims involving superfruits have been specifically about antioxidants, with over one in 10 claims submitted to EFSA addressing antioxidant properties. Although many superfruit ingredients have been lauded for their cellular protection properties, only acerola is associated with an endorsed health claim by EFSA.

According to the Cochrane Library, a significant 63% of clinical trials undertaken on superfruits in the period 2009 to 2012 were able to establish a cause and effect relationship. This should prompt further testing in future to establish the positive roles superfruits play in managing certain health conditions.

Your key questions answered

• What are the more unusual superfruits that have potential to be successfully applied to food and drinks products?
• What health claims are being made about superfruits and how will these impact food and drinks players?
• What clinical trials are being undertaken on superfruits and how can these be useful to food and drinks companies?
• What patent applications have recently been filed on these superfruits and what will be the impact on their FMCG usage?
• How will regulations impact the sale of these superfruits in global markets?